Longevity drugs and Artificial Intelligence trends
David Sinclair is preparing human tests of a reprogramming drug aimed at whole-body rejuvenation. A broader technology roundup tracks major Artificial Intelligence developments, policy fights, chip restrictions, and emerging biotechnology.
Artificial Intelligence tools and security risks reshape developer workflows
New Artificial Intelligence development tools, compute infrastructure deals, and automation products are advancing quickly. Security incidents and bot-driven traffic are also raising fresh concerns for developers and organizations.
Financial services firms struggle to govern enterprise Artificial Intelligence adoption
Financial institutions are adopting Artificial Intelligence faster than governance teams can monitor it. Employee use of generative tools is creating visibility, data handling and compliance risks that bans alone are unlikely to solve.
Artificial Intelligence budgets rise while returns lag
Bain & Company finds companies are expanding Artificial Intelligence spending even as automation savings lag expectations. The value gap is tied to workflow design, governance, data access, and operating-model changes rather than technology alone.